Menlo Therapeutics Inc. (MNLO): Price and Financial Metrics


Menlo Therapeutics Inc. (MNLO)

Today's Latest Price: $1.35 USD

0.03 (-2.17%)

Updated Sep 4 4:00pm

Add MNLO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MNLO Stock Summary

  • With a year-over-year growth in debt of 3,390.94%, Menlo Therapeutics Inc's debt growth rate surpasses 99.06% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Menlo Therapeutics Inc is reporting a growth rate of 255.12%; that's higher than 94.8% of US stocks.
  • As for revenue growth, note that MNLO's revenue has grown 667.89% over the past 12 months; that beats the revenue growth of 98.83% of US companies in our set.
  • Stocks that are quantitatively similar to MNLO, based on their financial statements, market capitalization, and price volatility, are TRXC, COHR, RENN, FSLR, and CMRX.
  • MNLO's SEC filings can be seen here. And to visit Menlo Therapeutics Inc's official web site, go to www.menlotherapeutics.com.
MNLO Daily Price Range
MNLO 52-Week Price Range

MNLO Stock Price Chart Technical Analysis Charts


MNLO Price/Volume Stats

Current price $1.35 52-week high $7.48
Prev. close $1.38 52-week low $1.00
Day low $1.30 Volume 1,561,259
Day high $1.39 Avg. volume 2,817,431
50-day MA $1.63 Dividend yield N/A
200-day MA $2.95 Market Cap 226.38M

Menlo Therapeutics Inc. (MNLO) Company Bio


Menlo Therapeutics Inc., a biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials in pruritus associated with psoriasis and atopic dermatitis, and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is based in Redwood City, California.


MNLO Latest News Stream


Event/Time News Detail
Loading, please wait...

MNLO Latest Social Stream


Loading social stream, please wait...

View Full MNLO Social Stream

Latest MNLO News From Around the Web

Below are the latest news stories about Menlo Therapeutics Inc that investors may wish to consider to help them evaluate MNLO as an investment opportunity.

What You Need To Know About Menlo Therapeutics Inc.'s (NASDAQ:MNLO) Investor Composition

A look at the shareholders of Menlo Therapeutics Inc. (NASDAQ:MNLO) can tell us which group is most powerful...

Yahoo | September 9, 2020

VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September

BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference. H.C. Wainwright Annual Global Investment Conference Date:September 14 Time:2:30pm Eastern Time Webcast:https://wsw.com/webcast/hcw7/vyne/1630674    Cantor Fitzgerald Virtual Global Healthcare Conference Date:September 16 Time:10:00am Eastern Time Webcast:https://www.webcaster4.com/Webcast/Page/2495/37311    The Cantor Fitzgerald presentation will take the form of a “Fireside Chat” with analyst Louise Chen.About VYNE Therapeutics Inc. VYNE Thera...

Yahoo | September 9, 2020

Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics

VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "VYNE". The name and ticker symbol changes are effective as of the opening of trading today, September 8, 2020.

Yahoo | September 8, 2020

Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics

Company will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today it is changing its corporate name to VYNE Therapeutics Inc.  (“VYNE Therapeutics”). In connection with the name change, the Company’s common stock will begin trading under a new ticker symbol “VYNE”.  The name and ticker change will be effective at the opening of trading, Tuesday, September 8, 2020.  In addition, VYNE Therapeutics will ring the Nasdaq closing bell on September 8, at 4:00 PM ET. “Our new corporate branding, VYNE Therapeutics, reflects an evolution of our business which combines the strengths and traditions of our ...

Yahoo | September 2, 2020

Menlo Therapeutics' (MNLO) CEO David Domzalski on Q2 2020 Results - Earnings Call Transcript

Menlo Therapeutics Inc. (MNLO) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - Chief Executive Officer Matthew Wiley - Chief Commercial Officer Andrew Saik - Chief Financial Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Sadia Rahman...

SA Transcripts on Seeking Alpha | August 8, 2020

Read More 'MNLO' Stories Here

MNLO Price Returns

1-mo -5.59%
3-mo -22.86%
6-mo -48.67%
1-year -69.73%
3-year N/A
5-year N/A
YTD -70.91%
2019 12.62%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7241 seconds.